Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
Latest updates
September 20, 2023
Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year...
Platform
A-KINE™ PLATFORM
Reprogramming cell targets
Conditional modulation of cell functions to trigger therapeutic effects using cytokines with tuned-out off-target interactions and sites of action that are focused on intended disease targets.
Platform
ALLO-GLUE™ PLATFORM
Reprogramming protein targets
Altering form and function of intracellular proteins to induce them to engage in molecular interactions that promote inhibition of disease targets previously thought unapproachable.
Pipeline
Pipeline
Reprogramming the cancer immunity cycle
Overcoming immunosuppressive tumor microenvironments to unleash targeted immune system attack on human cancers and promote immunity.
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.
Latest updates
A-KINE™ PLATFORM
ALLO-GLUE™ PLATFORM
Pipeline
Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
September 20, 2023
Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year...
Reprogramming cell targets
Conditional modulation of cell functions to trigger therapeutic effects using cytokines with tuned-out off-target interactions and sites of action that are focused on intended disease targets.
Learn moreReprogramming protein targets
Altering form and function of intracellular proteins to induce them to engage in molecular interactions that promote inhibition of disease targets previously thought unapproachable.
Learn moreReprogramming the cancer immunity cycle
Overcoming immunosuppressive tumor microenvironments to unleash targeted immune system attack on human cancers and promote immunity.
Learn more